Azenta, INC 10-Q quarterly reports

Azenta, Inc. reported its Q2 2026 financial results, showing a slight revenue increase but a significant net loss driven by a $149.1 million goodwill impairment charge.

Azenta, Inc. reports a net loss of $15.4 million in Q1 2026, driven by a loss on assets held for sale, while advancing its strategic divestiture of the B Medical Systems business.

Azenta, Inc. reported a significant net loss for Q3 2025, primarily due to a substantial loss from discontinued operations, despite improvements in gross margin and reduced operating losses from continuing operations.

Azenta, Inc. announces a 5% increase in revenue for Q2 2025, driven by growth in Sample Management Solutions and Multiomics, while progressing with the planned sale of its B Medical Systems business.

Azenta's Q1 2025 shows revenue growth driven by Multiomics and Sample Management Solutions, alongside ongoing transformation efforts.

Azenta Inc. reported a net loss of $6.6 million for the third quarter of 2024, impacted by a significant goodwill impairment charge, despite a slight revenue increase.

Azenta's Q2 fiscal 2024 results show a net loss driven by a significant goodwill impairment, despite revenue growth in some segments.

Azenta Inc. experienced a 13% decrease in revenue in the first quarter of fiscal year 2024, primarily due to a significant drop in B Medical Systems revenue, despite growth in other segments.